Please login to the form below

Not currently logged in
Email:
Password:

delamanid

This page shows the latest delamanid news and features for those working in and with pharma, biotech and healthcare.

Study shows Otsuka's TB drug works even in worst cases

Study shows Otsuka's TB drug works even in worst cases

The analysis of data from phase IIb trials of Deltyba (delamanid) reveals that the drug can be effective even in cases of TB that are unlikely to respond to any other ... More new medicines are urgently needed to prevent XDR-TB from becoming a death

Latest news

  • R&D productivity takes off R&D productivity takes off

    Other first-in-class agents include: Merck &Co's PAR-1 antagonist Zontivity (vorapaxar), a novel antiplatelet agent; AstraZeneca's PARP inhibitor Lynparza (olaparib) for cancer; Otsuka's Deltyba (delamanid), a

  • Otsuka wins approval for TB drug Deltyba Otsuka wins approval for TB drug Deltyba

    This week the European Commission granted the Japanese firm authorisation to market Deltyba (delamanid) almost two months after backing Johnson &Johnson's Sirturo (bedaquiline) in a similar indication. ... was “ too short to establish the effectiveness

  • Tuberculosis: treatment and prevention Tuberculosis: treatment and prevention

    Otsuka Pharmaceutical is developing delamanid, a nitro-dihydroimidazo-oxazole derivative, for use as an oral anti-TB agent. ... Delamanid is also in phase 3 development in the US, Estonia, India, Latvia, Lithuania, Moldova, Peru, South Africa and the

  • J&J gets EU green light for novel TB drug J&J gets EU green light for novel TB drug

    delamanid), which was given a conditional approval last November along with Lucane Pharma SA's para-aminosalicylic acid.

  • Cell wall inhibitors for bacterial infections Cell wall inhibitors for bacterial infections

    The nitro-dihydroimidazo-oxazole derivative Delamanid (Deltyba; Otsuka Pharmaceutical) inhibits mycolic acid synthesis and thus the formation of the mycobacterial cell envelope.

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Solaris Health

The beauty of detail: an effective, compelling medical communications campaign requires each component to be carefully planned, expertly crafted and...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics